The rise of new psychoactive substances and psychiatric implications: A wide‐ranging, multifaceted challenge that needs far‐reaching common legislative strategies
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
The ever‐growing number of novel psychoactive substances (NPS) that have been surfacing globally, as well as related changes in drug abuse trends, undoubtedly constitute a difficult and multifaceted challenge for psychiatry. The intake and abuse of such substances has been linked to a risk of psychopathological disturbances, which stem from imbalances of a range of neurotransmitter pathways and receptors. Through an analysis of relevant research articles and reviews (particularly those outlining NPS neurological and cerebral mechanisms of action and psychopathological consequences arising from NPS abuse; research papers more closely focused on chemical/pharmacological aspects have been ruled out), through a systematic analysis of Pubmed, Medline, PsycLIT and EMBASE literature, as well as data released by health care institutions and drug enforcement agencies (among which the World Health Organization, the United Nations Office on Drugs and Crime, the European Monitoring Centre for Drugs and Drug Addiction, Eurojust, the Novel Psychoactive Treatment UK Network, the Court of Justice of the European Union), the authors aimed to elaborate on the most relevant data relative to NPS‐related psychiatric effects, focusing on the conceptual and definition‐related complexities inherent to NPS, clinical management and motivations for NPS use; moreover, an effort has been made to highlight the possible measures in order to tackle the unremitting rise of such elusive and potentially harmful substances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McCann, U. D., Wong, D. F., Yokoi, F., Villemagne, V., Dannals, R. F., & Ricaurte, G. A. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-20-08417.1998 · Cited by 602 · cited 2×
“methcathinone users may present decreased striatal dopamine transporter density on positron emission tomography scans (McCann et al., 1998), suggesting the potential risk for long-term psychiatric problems”
Background
Cited by
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
Metabolic characterization of the new benzimidazole synthetic opioids - nitazenes
Jadhav, G. R., & Fasinu, P. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1434573 · Cited by 29
Teenager Substance Use on Reddit: Mixed Methods Computational Analysis of Frames and Emotions
Zhang, X., Zhu, J., Kenne, D. R., & Jin, R. (2025) · Journal of Medical Internet Research · doi:10.2196/59338 · Cited by 8
The Future of Deadly Synthetic Opioids: Nitazenes and Their International Control
Lassi, N., & Jiang, S. (2025) · Global Policy · doi:10.1111/1758-5899.70000 · Cited by 9
Metadata
- Authors
- Rinaldi, R., Bersani, G., Marinelli, E., & Zaami, S.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2020-03-07
- Volume
- 35
- Issue
- 3
- Pages
- e2727-e2727
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W3009292303
- Cited by
- 63
- References
- 1
- FWCI
- 14.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.